

- **Name:** Atsushi Ohtsu
 - **Current Position & Affiliation:** Director, National Cancer Center Hospital East
 - **Country:** Japan
-

• **Educational Background:**

- MD from Tohoku University in 1983
- PhD from Tohoku University in 1992

• **Professional Experience:**

- From 1992, he has been working at Gastrointestinal Oncology department in National Cancer Center Hospital East excluding the period of his visit to MD Anderson Cancer Center, USA in 1997. In 2012, he has become the Director of Exploratory Oncology Research & Clinical Trial Center (NCC-EPOC), which involves preclinical, TR, and early/exploratory clinical research in NCC. During the period between 2015 and 2016, he had acted as a scientific board member of Japan Agency for Medical Research and Development (AMED). In 2016, he became the Director of National Cancer Center Hospital East.

• **Professional Organizations:**

- Dr. Ohtsu acted as a member of the international affairs committee in American Society of Clinical Oncology and is also acting as a Director of the Japanese Society of Medical Oncology (serving as the chair of international affair committee) and Japanese Cancer Association as a Vice President. He is also serving as a member or advisory expert of various committees in PMDA, MHLW, and MEXT.

• **Main Scientific Publications:**

1. Izumi H, Matsumoto S, Ohtsu A, et al: The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. *Nature*, Dec;600(7888):319-323, 2021
2. Nakamura Y, Okamoto W, Ohtsu A, et al: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. *Nature Med*, Nov;27(11):1899-1903, 2021
3. Yamazaki K, Yamanaka T, Ohtsu A, et al: Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. *Ann Oncol* 32: 77-84, 2021
4. Nakamura Y, Fujisawa T, Ohtsu A, et al: SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors. *Cancer Sci*, Nov;112(11):4425-4432, 2021
5. Nakamura Y, Taniguchi H, Ohtsu A, et al: Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. *Nature Med*, 26: 1859-1864, 2020
6. Yoshino T, Yamanaka T, Ohtsu A, et al: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial. *JAMA Oncol* 5: 1574-0581, 2019

7. Tabernero J, Hoff PM, Ohtsu A, et al: Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 19: 1372-1384, 2018
8. Shitara K, Özgüroğlu M, Ohtsu A et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2018 Jul 14;392(10142):123-133.
9. Shinozaki E, Yoshino T, Ohtsu A, et al: Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. *Br J Cancer*. 2017 Nov 7;117(10):1450-1458
10. Kuboki Y, Nishina T, Ohtsu A, et al: TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. *Lancet Oncol* 18(9):1172-1181, 2017
11. Yoh K, Seto T, Ohtsu A, et al: Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. *Lancet Respir Med*, 5(1):42-50, 2017
12. Yamanaka T, Oki E, Ohtsu A, et al: 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. *J Clin Oncol*. 2016 Aug 20;34(24):2906-13.
13. Mayer RJ, Van Cutsem E, Ohtsu A, et al; Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*.; 372(20): 1909-19, 2015
14. Ohtsu A, Ajani JA, Bai YX, et al: Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. *J Clin Oncol*. 31(31):3935-43, 2013
15. Yoshino T, Mizunuma N, Ohtsu A, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol*. 13(10):993-1001, 2012
16. Ohtsu A, Shah M, Van Cutsem E, et al: Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. *J Clin Oncol*, 29(30):3968-3976, 2011
17. Bang YJ, Van Cutsem E, Ohtsu A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 376: 687-697, 2010
18. Ohtsu A, Yoshida S, Saijo N: Disparities in gastric cancer chemotherapy between the East and West. *J Clin Oncol* 24: 2188-2196, 2006
19. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol*, 21: 54-59, 2003
20. Ohtsu A, Boku N, Muro K, et al: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. *J Clin Oncol*, 17:2915-2921, 1999